FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2169874604> ?p ?o ?g. }

• W2169874604 endingPage "1639" @default.
• W2169874604 startingPage "1627" @default.
• W2169874604 abstract "PURPOSE To present safety and efficacy results obtained in treatment of a cohort of patients with unresectable hepatocellular carcinoma (HCC) with use of 90Y microspheres (TheraSphere). PATIENTS AND METHODS Forty-three consecutive patients with HCC were treated with 90Y microspheres over a 4-year period. Patients were treated by liver segment or lobe on one or more occasions based on tumor distribution, liver function, and vascular flow dynamics. Patients were followed for adverse events, objective tumor response, and survival. Patients were stratified into three risk groups according to method of treatment and risk stratification (group 0, segmental; group 1, lobar low-risk; group 2, lobar high-risk) and Okuda and Child-Pugh scoring systems. RESULTS Based on follow-up data from 43 treated patients, 20 patients (47%) had an objective tumor response based on percent reduction in tumor size and 34 patients (79%) had a tumor response when percent reduction and/or tumor necrosis were used as a composite measure of tumor response. There was no statistical difference among the three risk groups with respect to tumor response. Survival times from date of diagnosis were different among the risk groups (P < .0001). Median survival times were 46.5 months, 16.9 months, and 11.1 months for groups 0, 1, and 2, respectively. Median survival times of 24.4 months and 12.5 months by Okuda scores of I and II, respectively, were achieved (mean, 25.8 months vs 13.1). Patients had median survival times of 20.5 months and 13.8 months according to Child class A and class B/C disease, respectively (mean, 22.7 months vs 13.6 months). Patients classified as having diffuse disease exhibited decreased survival and reduced tumor response. There were no life-threatening adverse events related to treatment. CONCLUSIONS Use of 90Y microspheres (TheraSpheres) provides a safe and effective method of treatment for a broad spectrum of patients presenting with unresectable HCC. Further investigation is warranted. To present safety and efficacy results obtained in treatment of a cohort of patients with unresectable hepatocellular carcinoma (HCC) with use of 90Y microspheres (TheraSphere). Forty-three consecutive patients with HCC were treated with 90Y microspheres over a 4-year period. Patients were treated by liver segment or lobe on one or more occasions based on tumor distribution, liver function, and vascular flow dynamics. Patients were followed for adverse events, objective tumor response, and survival. Patients were stratified into three risk groups according to method of treatment and risk stratification (group 0, segmental; group 1, lobar low-risk; group 2, lobar high-risk) and Okuda and Child-Pugh scoring systems. Based on follow-up data from 43 treated patients, 20 patients (47%) had an objective tumor response based on percent reduction in tumor size and 34 patients (79%) had a tumor response when percent reduction and/or tumor necrosis were used as a composite measure of tumor response. There was no statistical difference among the three risk groups with respect to tumor response. Survival times from date of diagnosis were different among the risk groups (P < .0001). Median survival times were 46.5 months, 16.9 months, and 11.1 months for groups 0, 1, and 2, respectively. Median survival times of 24.4 months and 12.5 months by Okuda scores of I and II, respectively, were achieved (mean, 25.8 months vs 13.1). Patients had median survival times of 20.5 months and 13.8 months according to Child class A and class B/C disease, respectively (mean, 22.7 months vs 13.6 months). Patients classified as having diffuse disease exhibited decreased survival and reduced tumor response. There were no life-threatening adverse events related to treatment. Use of 90Y microspheres (TheraSpheres) provides a safe and effective method of treatment for a broad spectrum of patients presenting with unresectable HCC. Further investigation is warranted." @default.
• W2169874604 created "2016-06-24" @default.
• W2169874604 creator A5001743405 @default.
• W2169874604 creator A5019417714 @default.
• W2169874604 creator A5021169621 @default.
• W2169874604 creator A5026427052 @default.
• W2169874604 creator A5030666817 @default.
• W2169874604 creator A5032746255 @default.
• W2169874604 creator A5033464248 @default.
• W2169874604 creator A5046835105 @default.
• W2169874604 creator A5087536545 @default.
• W2169874604 date "2005-12-01" @default.
• W2169874604 modified "2023-10-18" @default.
• W2169874604 title "Treatment of Unresectable Hepatocellular Carcinoma with Use of 90Y Microspheres (TheraSphere): Safety, Tumor Response, and Survival" @default.
• W2169874604 cites W1967974274 @default.
• W2169874604 cites W1970303657 @default.
• W2169874604 cites W1972358289 @default.
• W2169874604 cites W1984547650 @default.
• W2169874604 cites W1988608956 @default.
• W2169874604 cites W2006298485 @default.
• W2169874604 cites W2010047598 @default.
• W2169874604 cites W2011368783 @default.
• W2169874604 cites W2012145535 @default.
• W2169874604 cites W2019958865 @default.
• W2169874604 cites W2020215421 @default.
• W2169874604 cites W2033444814 @default.
• W2169874604 cites W2033802014 @default.
• W2169874604 cites W2039918489 @default.
• W2169874604 cites W2046177464 @default.
• W2169874604 cites W2051158224 @default.
• W2169874604 cites W2052552898 @default.
• W2169874604 cites W2060073297 @default.
• W2169874604 cites W2060123467 @default.
• W2169874604 cites W2065475260 @default.
• W2169874604 cites W2069514137 @default.
• W2169874604 cites W2070567343 @default.
• W2169874604 cites W2074333538 @default.
• W2169874604 cites W2107776611 @default.
• W2169874604 cites W2120579772 @default.
• W2169874604 cites W2121707384 @default.
• W2169874604 cites W2125763116 @default.
• W2169874604 cites W2128320935 @default.
• W2169874604 cites W2139248078 @default.
• W2169874604 cites W2146094362 @default.
• W2169874604 cites W2165336841 @default.
• W2169874604 cites W2315948693 @default.
• W2169874604 cites W2325600277 @default.
• W2169874604 cites W2591170673 @default.
• W2169874604 cites W3041047318 @default.
• W2169874604 cites W4239330499 @default.
• W2169874604 doi "https://doi.org/10.1097/01.rvi.0000184594.01661.81" @default.
• W2169874604 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/16371529" @default.
• W2169874604 hasPublicationYear "2005" @default.
• W2169874604 type Work @default.
• W2169874604 sameAs 2169874604 @default.
• W2169874604 citedByCount "371" @default.
• W2169874604 countsByYear W21698746042012 @default.
• W2169874604 countsByYear W21698746042013 @default.
• W2169874604 countsByYear W21698746042014 @default.
• W2169874604 countsByYear W21698746042015 @default.
• W2169874604 countsByYear W21698746042016 @default.
• W2169874604 countsByYear W21698746042017 @default.
• W2169874604 countsByYear W21698746042018 @default.
• W2169874604 countsByYear W21698746042019 @default.
• W2169874604 countsByYear W21698746042020 @default.
• W2169874604 countsByYear W21698746042021 @default.
• W2169874604 countsByYear W21698746042022 @default.
• W2169874604 countsByYear W21698746042023 @default.
• W2169874604 crossrefType "journal-article" @default.
• W2169874604 hasAuthorship W2169874604A5001743405 @default.
• W2169874604 hasAuthorship W2169874604A5019417714 @default.
• W2169874604 hasAuthorship W2169874604A5021169621 @default.
• W2169874604 hasAuthorship W2169874604A5026427052 @default.
• W2169874604 hasAuthorship W2169874604A5030666817 @default.
• W2169874604 hasAuthorship W2169874604A5032746255 @default.
• W2169874604 hasAuthorship W2169874604A5033464248 @default.
• W2169874604 hasAuthorship W2169874604A5046835105 @default.
• W2169874604 hasAuthorship W2169874604A5087536545 @default.
• W2169874604 hasConcept C126322002 @default.
• W2169874604 hasConcept C141071460 @default.
• W2169874604 hasConcept C197934379 @default.
• W2169874604 hasConcept C2777546739 @default.
• W2169874604 hasConcept C2778019345 @default.
• W2169874604 hasConcept C2992208098 @default.
• W2169874604 hasConcept C71924100 @default.
• W2169874604 hasConcept C72563966 @default.
• W2169874604 hasConcept C90924648 @default.
• W2169874604 hasConceptScore W2169874604C126322002 @default.
• W2169874604 hasConceptScore W2169874604C141071460 @default.
• W2169874604 hasConceptScore W2169874604C197934379 @default.
• W2169874604 hasConceptScore W2169874604C2777546739 @default.
• W2169874604 hasConceptScore W2169874604C2778019345 @default.
• W2169874604 hasConceptScore W2169874604C2992208098 @default.
• W2169874604 hasConceptScore W2169874604C71924100 @default.
• W2169874604 hasConceptScore W2169874604C72563966 @default.
• W2169874604 hasConceptScore W2169874604C90924648 @default.
• W2169874604 hasIssue "12" @default.
• W2169874604 hasLocation W21698746041 @default.

• next